The North America Implantable Cardioverter Defibrillator Market would witness market growth of 5.4% CAGR during the forecast period (2023-2030).
Technological advances and product innovations, such as Epsila EV MRI SureScan and Aurora Extravascular (EV)-ICD MRI SureScan by Medtronic, offer optimistic solutions with reduced complications and enhanced placement techniques. Moreover, the prevalence of sudden cardiac arrest is on the rise in emerging nations. The prevalence of sudden cardiac arrest is anticipated to rise due to the growth of specific risk factors like smoking, obesity, and sedentary lifestyle, which is anticipated to raise demand for ICD during the forecast period.
The ICD has seen continuous technological advancements, leading to smaller, more efficient devices with improved battery life. These advancements have made ICDs more comfortable for patients and easier for healthcare providers to implant. Miniaturization of ICDs has been a significant trend, allowing for less invasive procedures and reduced scarring. Smaller devices also improve patient comfort and reduce the risk of infection. Remote monitoring capabilities have become increasingly important in ICDs. These devices can transmit data and alerts to healthcare providers, allowing for proactive patient care and early detection of potential issues.
North America has a significant prevalence of cardiovascular diseases, including arrhythmias, heart failure, and coronary artery disease. ICDs are essential in preventing sudden cardiac death in patients with these conditions. North America is known for its advanced medical technology and innovation. Manufacturers in the region and around the world develop state-of-the-art ICDs with features such as remote monitoring, MRI compatibility, and sophisticated algorithms for arrhythmia detection. The adoption and utilization of ICDs in North America continue to grow as healthcare providers and patients recognize the value of these devices in managing cardiac conditions and reducing the risk of sudden cardiac death. Advances in technology, research, and patient care contribute to the ongoing development of the ICD in the region.
The US market dominated the North America Implantable Cardioverter Defibrillator Market, By Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1,554.6 million by 2030. The Canada market is exhibiting a CAGR of 7.8% during (2023 - 2030). Additionally, The Mexico market would experience a CAGR of 6.9% during (2023 - 2030).
Based on Type, the market is segmented into Biventricular Devices, Dual Chamber ICDs and Single Chamber ICDs. Based on Product Type, the market is segmented into Transvenous and Subcutaneous. Based on NYHA Class, the market is segmented into NYHA Class II and NYHA Class III. Based on End-Use, the market is segmented into Hospitals, Ambulatory Surgical Centers and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Implantable Cardioverter Defibrillator Market is Predict to reach $5.6 Billion by 2030, at a CAGR of 6.1%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Medtronic PLC, Biotronik SE & Co. KG, Boston Scientific Corporation, MicroPort Scientific Corporation, Stryker Corporation, ZOLL Medical Corporation (Asahi Kasei Corporation), LivaNova PLC, Koninklijke Philips N.V. and Getinge AB.
By Type
By Product Type
By NYHA Class
By End-use
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
